drugset / Trial / NCT05432141

A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

NCT05432141

Phase 4 Completed 3200 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell)(sIPV)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.

Timeline

Start
2022-06-13
Primary completion
2022-09-13
Completion
2022-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject DTaP vaccine Vaccine Intramuscular
Subject Hepatitis A inactivated vaccine Vaccine Intramuscular
Subject MMR vaccine Vaccine Intramuscular
Subject Sabin Inactivated Poliovirus Vaccine (Vero cell) Vaccine Intramuscular
Subject attenuated hepatitis A vaccine Vaccine Intramuscular

Indications